Back to Insights and Updates for ProvidersMay 2023

Removing certain drugs from white-bagging program

Tufts Health Direct  |  Tufts Health Plan Commercial  |  Tufts Medicare Preferred

Effective for dates of service beginning July 1, 2023, certain medications will no longer be offered as part of Tufts Health Plan’s office-administered medical drug/white bagging program.

The drugs identified below will be removed from our Office-Administered Medical Drugs list for Tufts Health Direct, as well as for Tufts Health Plan Commercial and Tufts Medicare Preferred, and will no longer be available through CVS Caremark:

Aranesp Arzerra
Avastin Epogen
Gel-One GenVisc 850
Hyalgan Leukine
Lucentis Monovisc
Mozobil Neulasta
Neupogen Octreotide
Orthovisc Procrit
Sandostatin Supartz
Synvisc Synvisc-One
Vantas Zarxio

Providers can continue to buy and bill these medications once prior authorization has been obtained. (You can request prior authorization in a number of ways, but we recommend submitting requests electronically through PromptPA for its ease of use and quick turnaround times.)

In addition, some of the medications may be available under Tufts Health Plan’s Pharmacy benefit. Please refer to the relevant plan’s online formulary to confirm Pharmacy coverage of drug.

Audrey Kleinberg,
Director, Provider Relations & Communications

Annmarie Dadoly,
Senior Manager, Provider Communications

Joseph O’Riordan, Jesse Salvato, Stephen Wong,

Kristin Edmonston,
Production Coordinator

Kristina Cicelova,
Graphic Designer